Boundless Bio, Inc. (BOLD)

Market Cap	34.96M +20.6%
Revenue (ttm)	n/a
Net Income	-58.20M
EPS	-2.60
Shares Out	22.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,657
Open	1.556
Previous Close	1.580
Day's Range	1.530 - 1.610
52-Week Range	0.961 - 1.780
Beta	-0.25
Analysts	Strong Buy
Price Target	4.00 (+156.41%)
Earnings Date	May 8, 2026

About BOLD

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2024
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLD
• Website: https://boundlessbio.com

Analyst Summary

According to 3 analysts, the average rating for BOLD stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 156.41% from the latest price.

Price Target

$4.0

(156.41% upside)

Analyst Consensus: Strong Buy